Which Cannabis Brands Survive the 2026 Hemp Ban

On November 12, 2026, Section 781 of H.R. 5371 redefines hemp by total-THC content and caps every container at 0.4mg of THC. That single sentence ends the intoxicating hemp-derived product market as anyone reading this currently understands it. Most operators in that market do not survive in their current form. Some pivot. Some die. A small number of state-licensed brands inherit a great deal of demand they did nothing in particular to earn.

This is a taxonomy of who falls where. Read it as a betting card if you want to. The question every brand faces is the same: where does your revenue come from, and is that source still legal at midnight on November 12? The answers separate the survivors from the cleanup.

The state-licensed survivors

A brand whose entire business sits inside state-regulated dispensary channels barely notices the ban as a regulatory event. They notice it as a demand event. Customers who were buying delta-8 gummies on a gas station counter for $15 are about to become customers who walk into a dispensary and pay $25 for a real product. Every state-licensed edibles brand benefits from that migration. The differences are about who is positioned to capture the most of it.

Wyld. Oregon-built, now in roughly a dozen state markets. Real-fruit gummies, disciplined dosing (10mg standard, 5mg in their lower-dose lines), strong CBN sleep SKU. Wyld has been operating as a state-licensed brand from day one and never tried to skim revenue off the hemp-derived side. They have manufacturing capacity in multiple states, retail relationships with most serious dispensaries, and brand recognition outside the cannabis-obsessive demographic. Net position: positive. Probably the single biggest beneficiary of demand migration in the gummy category.

Kiva. California's gummy and chocolate incumbent. Their Camino sub-brand owns the mood-targeted gummy concept in dispensary retail outright, with no real competitor doing it at the same scale. Kiva has the production infrastructure, the SKU breadth, and the licensing footprint to absorb a meaningful chunk of new demand. The risk is that Kiva sometimes prices high relative to what migrating hemp customers expect to pay, and a $30 bag feels different to a customer who was paying $15 at a gas station last month. Net position: positive, with a pricing question they will have to answer.

Wana. Multi-state operator with one of the broadest dispensary footprints in the category. Wana Quick (the fast-acting gummy line) is genuinely good and priced reasonably. Wana has been quietly building distribution while flashier brands chased press. Net position: strongly positive.

Papa & Barkley. Wellness-positioned, originated in California, known for the Releaf line of CBD-forward and ratio products. Their customer base overlaps significantly with the hemp-derived CBD-plus-THC consumer who is about to lose their preferred product. P&B can credibly absorb that customer at the dispensary. Net position: positive.

1906. Functional edibles (Midnight for sleep, Go for energy, Genius for focus). Hemp customers who were buying mood-targeted hemp gummies because their dispensary did not carry an equivalent are now going to find 1906 doing exactly what they wanted, with regulated dosing and verified ingredients. Net position: positive.

Smokiez, Mary's Medicinals, Camino (Kiva sub-brand), Korova, Petra (Kiva sub-brand). All state-licensed, all benefit from the same demand-migration story. Smokiez in particular has an interesting position because they were one of the early dispensary edibles brands and have brand equity with the patient demographic that does not move on price.

The pivoters

These are operators who built businesses on the hemp side, saw the ban coming, and have been moving toward state-licensed channels for the past 12 to 24 months. Whether the pivot completes in time is the open question.

Cookies. Brand-licensing operation across multiple states with state-licensed product distribution through local cultivation and manufacturing partners. Cookies has stayed largely out of the intoxicating hemp-derived space because their high-end positioning depends on dispensary channel exclusivity. The brand is structurally insulated from the ban. Net position: positive. Worth saying that Cookies has its own corporate problems unrelated to this ban, and those problems will not be solved by the regulatory tailwind.

Stiiizy. California-headquartered, primarily a vape brand but with growing edibles presence. Stiiizy is state-licensed across most of its footprint and has not been a meaningful player in hemp-derived channels. Net position: positive on the edibles side. Vape still drives most of their volume.

Cann. The cannabis-infused beverage incumbent. Started as a state-licensed product, expanded into hemp-derived versions to chase the THC-beverage trend, and now has to decide which side of that line they end up on. The hemp-derived Cann SKUs go away on November 12. The state-licensed business continues. Whether Cann's investors are content with the state-licensed business alone depends on what they were promised at the last raise. Net position: mixed, leaning negative on overall revenue, neutral on brand survival.

The exposed

These are operators whose growth stories ran through the hemp-derived channel. The growth story ends on November 12. What happens next depends on cash, contracts, and how committed their investors were to the original thesis.

Delta Munchies, 3Chi, Hometown Hero, Bearly Legal, Mellow Fellow, URB, Cake. Hemp-derived brands operating primarily in delta-8, delta-9 hemp gummies, THCA flower, or some combination. Their entire intoxicating product line becomes federally illegal on November 12. Some of these operators have been quietly building state-licensed pathways and will continue under different names or as licensing partners with state-licensed manufacturers. Most will contract to a fraction of their current size or shut down. Net position: severely negative across the category, with individual outcomes depending on cash reserves and the realism of management.

Charlotte's Web. Built the CBD category almost single-handedly. Currently hemp-primary, but the product line is overwhelmingly CBD isolate as opposed to intoxicating hemp-derived THC. Most of their SKUs will meet the new 0.4mg cap and remain legal. Charlotte's Web is more resilient to the ban than most hemp brands because they never pivoted hard into intoxicating products, but their revenue takes a hit on any SKUs that exceed the threshold. Net position: neutral to mildly negative.

cbdMD, Joy Organics, CBDistillery. Same story as Charlotte's Web at smaller scale. Hemp-CBD businesses that flirted with intoxicating SKUs as the trend moved that way. The CBD core business survives the ban. The intoxicating SKUs do not. Net position: neutral, with a revenue trim.

The pretenders

A subset of hemp-derived operators are running media campaigns suggesting the ban will be delayed, watered down, or repealed before it takes effect. Some of this is genuine policy advocacy and some is a stalling tactic to keep the cash register ringing through Q3 2026. Customers who buy into this narrative end up with inventory that loses legal status while sitting on their counter.

The Cannabinoid Safety and Regulation Act is the most credible amendment proposal currently under discussion. It has not advanced out of committee. The U.S. Hemp Roundtable is lobbying for changes. None of the active legislative vehicles is on a path to amend Section 781 before November 12. A reader who bets the other way on a 90-day product purchase between now and the deadline is betting against the base rate.

The ones nobody is talking about

The single most under-discussed beneficiary of the ban is the manufacturer who already has state-licensed production capacity sitting partially idle. There are facilities in Michigan, Massachusetts, and Oregon running at 50 to 70 percent of installed capacity because their state markets are oversaturated relative to demand. A national demand surge that dispensaries cannot meet from existing inventory pulls those facilities up the curve. This is a supply-chain story, and it shows up in the form of dispensary shelves restocking faster than expected through Q1 and Q2 of 2027.

The other under-discussed group is the legacy California craft brands who never expanded out of state because the economics never worked. Some of them now find that the economics work, because national demand is concentrated into a smaller compliant supply base. Whether they can move quickly enough to capitalize is a separate question. Most of them will not. A few will, and those few become the most interesting brand stories of 2027.

How to read this if you're a customer

If a brand you currently buy is on the exposed list, your product goes away. Buy through November 11 if you want a personal stockpile, recognizing that an unopened jar of delta-8 gummies in your kitchen drawer on November 13 is no longer a federally legal product, regardless of when you bought it. Personal-use prosecution of small quantities is rare. Personal-use prosecution is also not zero.

If a brand you currently buy is on the survivor list, you keep buying. Prices may tick up 5 to 15 percent through the first half of 2027 as supply catches up to migrated demand. Plan around it.

If you live in a state without a functioning medical or recreational program and hemp-derived was your only access channel, you lose access on November 12 with no immediate replacement. Texas, Tennessee, Georgia, North Carolina, Indiana, Wisconsin, Iowa, Idaho, Kansas, Nebraska, South Dakota, and several others fall into this category. The political pressure that builds in those states through 2027 is one of the more interesting downstream effects of this ban, and it is also outside the scope of a brand-survival piece.

One last thing

A brand surviving the ban is not the same as a brand being good. Several of the survivors on this list make products we have actively recommended against in dosing or value reviews. The ban does not fix those problems. It does mean the surviving brands have less competitive pressure to fix them, which is a slightly worse situation for the consumer than it sounds. The brands on the exposed list include several operators who made genuinely good products at fair prices in a regulatory loophole that was not built to last. Some of those products were better than what survives.

This is what regulatory consolidation looks like in real time. The brands that win are the ones that built compliance into the foundation. The brands that lose are the ones that built growth on a federal definition that was always going to get rewritten.